Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HTlF receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

Abstract: A system for determining densities and proportions of phases in a multi-phase fluid flow (MFF) that can include an oil phase, a water phase, and a gas phase from a well. The system includes a first density sensor that senses the MFF at locations where the phases of the MFF are often separated, a second density sensor senses the MFF from the output of a phase mixer-homogenizer, and a third density sensor that senses, in real time, the MFF where the gas phase starts to separate or has separated from the liquid phase but where the liquid phases have not separated. The system also includes one or more processors for executing one or more programs to determine a density of the oil phase, a density of the water phase, a density of the gas phase, and proportions of phases including a water cut and a gas volume fraction based on readings from the first, second, and third density sensors.

Abstract: A coated metal pigment that has excellent passivation, dispersion and adhesion properties, a method for producing the coated metal pigment and a coating composition that includes the coated metal pigment are described.

Abstract: Acoustic waveguides are disclosed for mounting to a conduit. The acoustic waveguides provide a mounting area that minimizes the effect of the mount on the acoustic wave traveling through the waveguide while providing an effective seal, even under high pressure conditions.

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract: Acoustic waveguides are disclosed for mounting to a conduit. The acoustic waveguides provide a mounting area that minimizes the effect of the mount on the acoustic wave traveling through the waveguide while providing an effective seal, even under high pressure conditions.

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract: Acoustic waveguides are disclosed for mounting to a conduit. The acoustic waveguides provide a mounting area that minimizes the effect of the mount on the acoustic wave traveling through the waveguide while providing an effective seal, even under high pressure conditions.

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract: The present invention relates to compounds of formula I: or pharmaceutically acceptable acid addition salts thereof, where; R1 is C1-C6 alkyl, substituted C1-C6 alkyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, C3-C7 cycloalkyl-C1-C3 alkyl, substituted C3-C7 cycloalkyl-C1-C3 alkyl, phenyl, substituted phenyl, heterocycle, or substituted heterocycle; R2 is hydrogen, C1-C3 alkyl, C3-C6 cycloalkyl-C1-C3 alkyl, or a group of formula II R3 is hydrogen or C1-C3 alkyl; R4 is hydrogen, halo, or C1-C3 alkyl; R5 is hydrogen or C1-C3 alkyl; R6 is hydrogen or C1-C6 alkyl; and n is an integer from 1 to 6 inclusively. The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.

Abstract: A pearlescent effect pigment having an opaque, dark or black color is disclosed. The black pearlescent pigment includes a platelet-shaped non-metal substrate, optionally an oxide layer, a template layer, and a metal layer. The pearlescent luster of the disclosed effect pigment is comparable to those of pure pearlescent effects. The disclosed method provides a cost-effective approach for the manufacturing of the disclosed effect pigment.

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract: The present invention provides methods and compositions for inhibiting calcium permeable cation conductance of red blood cells from individuals afflicted with sickle cell anemia. The method comprises exposing the cells to the peptide GsMTx4 and/or variants thereof.

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).

Abstract: A colored system including a coated substrate and a color pigment that adheres to the coated substrate, and a method for producing the colored system are described. The disclosed method adheres effectively the color pigments to the coated substrates. The resulting colored system avoids their separation during coating applications. The colored metallic paints/inks can be prepared by mixing a color pigment solution with a coated substrate solution. The resulting colored system displays vivid color and strong metallic luster.

Abstract: A coated pigment that includes polymer encapsulations which act as a pigment dispersant and film forming agent, coating systems that include the coated pigment and methods for producing the coated pigment and the coating system are described. The polymer encapsulations of the coated pigments allow the coated pigments that are included in the coating system to be dispersed without the addition of any other dispersants and/or resins. Thus, the disclosed coated pigments simplify the process of making coating systems. The disclosed coated pigments also extend the shelf-life of the coating systems, and provide a final coating with enhanced pigment orientation and aesthetics.

Abstract: A coated platelet that includes a robust polymer coating that has substantially uniform structures, a method for producing the coated platelet and a system that includes the coated platelet are described. The disclosed method involves immobilizing initiator molecules onto the surfaces of the platelet by using surface coupling groups and polymerization from initiating sites of the initiator anchored on the surface of the platelet. The disclosed method allows uniform growth of the polymer chains so as to produce robust coated platelets with a smooth coated surface. The disclosed system includes only the disclosed coated platelet and a solvent and eliminates the need to add polymer resins separate from the resins that are covalently attached to the platelet.

Abstract: A pearlescent effect pigment having an opaque, dark or black color is disclosed. The black pearlescent pigment includes a platelet-shaped non-metal substrate, optionally an oxide layer, a template layer, and a metal layer. The pearlescent luster of the disclosed effect pigment is comparable to those of pure pearlescent effects. The disclosed method provides a cost-effective approach for the manufacturing of the disclosed effect pigment.

Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).